Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor

Biochemistry

Volumn 46, Issue 14, 2007, Pages 4360-4369

  Deng, Yiqun ^a   Zheng, Qi ^a   Ketas, Thomas J ^a   Moore, John P ^a   Lu, Min ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MEMBRANES; CALORIMETRY; DICHROISM; DISEASES; GLYCOPROTEINS;

CORECEPTOR PREFERENCE; FUSION INHIBITORS; TRYPTOPHAN;

PEPTIDES;

GLYCOPROTEIN GP 41; HYBRID PROTEIN; PROTEIN INHIBITOR; RECOMBINANT PROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; CALORIMETRY; CIRCULAR DICHROISM; CONTROLLED STUDY; DRUG INDICATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN ENGINEERING; PROTEIN EXPRESSION; STRUCTURE ANALYSIS; T LYMPHOCYTE;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; ANTI-HIV AGENTS; CELL FUSION; CELL LINE; CELLS, CULTURED; CHO CELLS; COCULTURE TECHNIQUES; CRICETINAE; CRICETULUS; DISULFIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; ESCHERICHIA COLI; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; LEUCINE; LEUKOCYTES, MONONUCLEAR; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN ENGINEERING; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; TRYPTOPHAN; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34147124231     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi7001289     Document Type: Article

References (68)

1. Richman, D. D. (2001) HIV chemotherapy, Nature 410, 995-1001.
2. Pillay, D., Taylor, S., and Richman, D. D. (2000) Incidence and impact of resistance against approved antiretroviral drugs, Rev. Med. Virol. 10, 231-253.
3. Moore, J. P., and Stevenson, M. (2000) New targets for inhibitors of HIV-1 replication, Nat. Rev. Mol. Cell Biol. 1, 40-49.
4. Kuritzkes, D. R. (1996) Clinical significance of drug resistance in HIV-1 infection, AIDS 10 (Suppl. 5), S27-31.
5. Coffin, J. M. (1995) HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy, Science 267, 483-489.
6. Mansky, L. M., Pearl, D. K., and Gajary, L. C. (2002) Combination of drugs and drug-resistant reverse transcriptase results in a multiplicative increase of human immunodeficiency virus type 1 mutant frequencies, J. Virol. 76, 9253-9259.
7. Matthews, T., Salgo, M., Greenberg, M., Chung, J., DeMasi, R., and Bolognesi, D. (2004) Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes, Nat. Rev. Drug Discovery 3, 215-225.
8. Klasse, P. J., Shattock, R. J., and Moore, J. P. (2006) Which topical microbicides for blocking HIV-1 transmission will work in the real world?, PLoS Med. 3.
9. Veazey, R. S., Klasse, P. J., Schader, S. M., Hu, Q., Ketas, T. J., Lu, M., Marx, P. A., Dufour, J., Colonno, R. J., Shattock, R. J., Springer, M. S., and Moore, J. P. (2005) Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion, Nature 438, 99-102.
10. Hunter, E., and Swanstrom, R. (1990) Retrovirus envelope glycoproteins, Curr. Top. Microbiol. Immunol. 157, 187-253.
11. Eckert, D. M., and Kim, P. S. (2001) Mechanisms of viral membrane fusion and its inhibition, Annu. Rev. Biochem. 70, 777-810.
12. Harrison, S. C. (2005) Mechanism of membrane fusion by viral envelope proteins, Adv. Virus Res. 64, 231-261.
13. Moore, J. P., and Doms, R. W. (2003) The entry of entry inhibitors: a fusion of science and medicine, Proc. Natl. Acad. Sci. U.S.A. 100, 10598-10602.
14. Chan, D. C., Fass, D., Berger, J. M., and Kim, P. S. (1997) Core structure of gp41 from the HIV envelope glycoprotein, Cell 89, 263-273.
15. Tan, K., Liu, J., Wang, J., Shen, S., and Lu, M. (1997) Atomic structure of a thermostable subdomain of HIV-1 gp41, Proc. Natl. Acad. Sci. U.S.A. 94, 12303-12308.
16. Weissenhorn, W., Dessen, A., Harrison, S. C., Skehel, J. J., and Wiley, D. C. (1997) Atomic structure of the ectodomain from HIV-1 gp41, Nature 387, 426-430.
17. Lu, M., Blacklow, S. C., and Kim, P. S. (1995) A trimeric structural domain of the HIV-1 transmembrane glycoprotein, Nat. Struct. Biol. 2, 1075-1082.
18. Skehel, J. J., and Wiley, D. C. (2000) Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin, Annu. Rev. Biochem. 69, 531-569.
19. Jiang, S., Lin, K., Strick, N., and Neurath, A. R. (1993) HIV-1 inhibition by a peptide, Nature 365, 113.
20. Wild, C. T., Shugars, D. C., Greenwell, T. K., McDanal, C. B., and Matthews, T. J. (1994) Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection, Proc. Natl. Acad. Sci. USA. 91, 9770-9774.
21. Kilby, J. M., Hopkins, S., Venetta, T. M., DiMassimo, B., Cloud, G. A., Lee, J. Y., Alldredge, L., Hunter, E., Lambert, D., Bolognesi, D., Matthews, T., Johnson, M. R., Nowak, M. A., Shaw, G. M., and Saag, M. S. (1998) Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry, Nat. Med. 4, 1302-1307.
22. Chen, C. H., Matthews, T. J., McDanal, C. B., Bolognesi, D. P., and Greenberg, M. L. (1995) A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion, J. Virol. 69, 3771-3777.
23. Furata, R. A., Wild, C. T., Weng, Y., and Weiss, C. D. (1998) Capture of an early fusion-active conformation of HIV-1 gp41, Nat. Struct. Biol. 5, 276-279.
24. Wild, C., Greenwell, T., Shugars, D., Rimsky-Clarke, L., and Matthews, T. (1995) The inhibitory activity of an HIV type 1 peptide correlates with its ability to interact with a leucine zipper structure, AIDS Res. Hum. Retroviruses 11, 323-325.
25. Chan, D. C., and Kim, P. S. (1998) HIV entry and its inhibition, Cell 93, 681-684.
26. Lu, M., and Kim, P. S. (1997) A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein, J. Biomol. Struct. Dyn. 15, 465-471.
27. Judice, J. K., Tom, J. Y., Huang, W., Wrin, T., Vennari, J., Petropoulos, C. J., and McDowell, R. S. (1997) Inhibition of HIV type 1 infectivity by constrained alpha-helical peptides: implications for the viral fusion mechanism, Proc. Natl. Acad. Sci. U.S.A. 94, 13426-13430.
28. Shu, W., Liu, J., Ji, H., Radigen, L., Jiang, S., and Lu, M. (2000) Helical interactions in the HIV-1 gp41 core reveal structural basis for the inhibitory activity of gp41 peptides, Biochemistry 39, 1634-1642.
29. Sia, S. K., Carr, P. A., Cochran, A. G., Malashkevich, V. N., and Kim, P. S. (2002) Short constrained peptides that inhibit HIV-1 entry, Proc. Natl. Acad. Sci. U.S.A. 99, 14664-14669.
30. Sia, S. K., and Kim, P. S. (2003) Protein grafting of an HIV-1-inhibiting epitope, Proc. Natl. Acad. Sci. U.S.A. 100, 9756-9761.
31. Jin, B. S., Ryu, J. R., Ahn, K., and Yu, Y. G. (2000) Design of a peptide inhibitor that blocks the cell fusion mediated by glycoprotein 41 of human immunodeficiency virus type 1, AIDS Res. Hum. Retroviruses 16, 1797-1804.
32. Doering, D. S., and Matsudaira, P. (1996) Cysteine scanning mutagenesis at 40 of 76 positions in villin headpiece maps the F-actin binding site and structural features of the domain, Biochemistry 35, 12677-12685.
33. Kunkel, T. A., Roberts, J. D., and Zakour, R. A. (1987) Rapid and efficient site-specific mutagenesis without phenotypic selection, Methods Enzymol. 154, 367-382.
34. Abrahamyan, L. G., Mkrtchyan, S. R., Binley, J., Lu, M., Melikyan, G. B., and Cohen, F. S. (2005) The cytoplasmic tail slows the folding of human immunodeficiency virus type 1 Env from a late prebundle configuration into the six-helix bundle, J. Virol. 79, 106-115.
35. Edelhoch, H. (1967) Spectroscopic determination of tryptophan and tyrosine in proteins, Biochemistry 6, 1948-1954.
36. Chen, Y. H., Yang, J. T., and Chau, K. H. (1974) Determination of the helix and beta form of proteins in aqueous solution by circular dichroism, Biochemistry 13, 3350-3359.
37. Johnson, M. L., Correia, J. J., Yphantis, D. A., and Halvorson, H. R. (1981) Analysis of data from the analytical ultracentrifuge by nonlinear least-squares techniques, Biophys. J. 36, 575-588.
38. Laue, T. M., Shah, B. D., Ridgeway, T. M., and Pelletier, S. L. (1992) in Analytical Ultracentrifugation in Biochemistry and Polymer Science (Harding, S. E., Rowe, A. J., and Horton, J. C., Eds.) pp 90-125, Royal Society of Chemistry, Cambridge.
39. Kozarsky, K., Penman, M., Basiripour, L., Haseltine, W., Sodroski, J., and Krieger, M. (1989) Glycosylation and processing of the human immunodeficiency virus type 1 envelope protein, J. Acquired Immune Defic. Syndr. 2, 163-169.
40. Trkola, A., Matthews, J., Gordon, C., Ketas, T., and Moore, J. P. (1999) A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor, J. Virol. 73, 8966-8974.
41. Ketas, T. J., Klasse, P. J., Spenlehauer, C., Nesin, M., Frank, I., Pope, M., Strizki, J. M., Reyes, G. R., Baroudy, B. M., and Moore, J. P. (2003) Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types, AIDS Res. Hum. Retroviruses 19, 177-186.
42. Trkola, A., Paxton, W. A., Monard, S. P., Hoxie, J. A., Siani, M. A., Thompson, D. A., Wu, L., Mackay, C. R., Horak, R., and Moore, J. P. (1998) Genetic subtype-independent inhibition of human immunodeficiency virus type 1 replication by CC and CXC chemokines, J. Virol. 72, 396-404.
43. Mosmann, T. (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays, J. Immunol. Methods 65, 55-63.
44. Beddows, S., Schulke, N., Kirschner, M., Barnes, K., Franti, M., Michael, E., Ketas, T., Sanders, R. W., Maddon, P. J., Olson, W. C., and Moore, J. P. (2005) Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1, J. Virol. 79, 8812-8827.
45. Herrera, C., Spenlehauer, C., Fung, M. S., Burton, D. R., Beddows, S., and Moore, J. P. (2003) Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same site, J. Virol. 77, 1084-1091.
46. Gordon, C. J., Muesing, M. A., Proudfoot, A. E., Power, C. A., Moore, J. P., and Trkola, A. (1999) Enhancement of human immunodeficiency virus type 1 infection by the CC-chemokine RANTES is independent of the mechanism of virus-cell fusion, J. Virol. 73, 684-694.
47. Wild, C., Oas, T., McDanal, C., Bolognesi, D., and Matthews, T. (1992) A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition, Proc. Natl. Acad. Sci. U.S.A. 89, 10537-10541.
48. Chan, D. C., Chutkowski, C. T., and Kim, P. S. (1998) Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target, Proc. Natl. Acad. Sci. U.S.A. 95, 15613-15617.
49. Eckert, D. M., Malashkevich, V. N., Hong, L. H., Carr, P. A., and Kim, P. S. (1999) Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket, Cell 99, 103-115.
50. Zhou, G., Ferrer, M., Chopra, R., Kapoor, T. M., Strassmaier, T., Weissenhorn, W., Skehel, J. J., Oprian, D., Schreiber, S. L., Harrison, S. C., and Wiley, D. C. (2000) The structure of an HIV-1 specific cell entry inhibitor in complex with the HIV-1 gp41 trimeric core, Bioorg. Med. Chem. 8, 2219-2227.
51. Ferrer, M., Kapoor, T. M., Strassmaier, T., Weissenhorn, W., Skehel, J. J., Oprian, D., Schreiber, S. L., Wiley, D. C., and Harrison, S. C. (1999) Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements, Nat. Struct. Biol. 6, 953-960.
52. Liu, S., Lu, H., Niu, J., Xu, Y., Wu, S., and Jiang, S. (2005) Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120, J. Biol. Chem. 280, 11259-11273.
53. Rimsky, L. T., Shugars, D. C., and Matthews, T. J. (1998) Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides, J. Virol. 72, 986-993.
54. Reeves, J. D., Miamidian, J. L., Biscone, M. J., Lee, F. H., Ahmad, N., Pierson, T. C., and Doms, R. W. (2004) Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity, J. Virol. 78, 5476-5485.
55. Kliger, Y., Gallo, S. A., Peisajovich, S. G., Munoz-Barroso, I., Avkin, S., Blumenthal, R., and Shai, Y. (2001) Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage, J. Biol. Chem. 276, 1391-1397.
56. Eron, J. J., Gulick, R. M., Bartlett, J. A., Merigan, T., Arduino, R., Kilby, J. M., Yangco, B., Diers, A., Drobnes, C., DeMasi, R., Greenberg, M., Melby, T., Raskino, C., Rusnak, P., Zhang, Y., Spence, R., and Miralles, G. D. (2004) Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV, J. Infect. Dis. 189, 1075-1083.
57. Shu, W., Ji, H., and Lu, M. (1999) Trimerization specificity in HIV-1 gp41: analysis with a GCN4 leucine zipper model, Biochemistry 38, 5378-5385.
58. Cao, W., Bracken, C., Kallenbach, N. R., and Lu, M. (2004) Helix formation and the unfolded state of a 52-residue helical protein, Protein Sci. 13, 177-189.
59. Harbury, P. B., Kim, P. S., and Alber, T. (1994) Crystal structure of an isoleucine-zipper trimer, Nature 371, 80-83.
60. Root, M. J., Kay, M. S., and Kim, P. S. (2001) Protein design of an HIV-1 entry inhibitor, Science 291, 884-888.
61. Ketas, T., Schader, S. M., Zurita, J., Teo, E., Polonis, V., Lu, M., Klasse, P. J., and Moore, J. P. (2007) Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes, Virology, in press.
62. Poveda, E., Rodes, B., Toro, C., Martin-Carbonero, L., Gonzalez-Lahoz, J., and Soriano, V. (2002) Evolution of the gp41 env region in HIV-infected patients receiving T-20, a fusion inhibitor, AIDS 16, 1959-1961.
63. Kilby, J. M., Lalezari, J. P., Eron, J. J., Carlson, M., Cohen, C., Arduino, R. C., Goodgame, J. C., Gallant, J. E., Volberding, P., Murphy, R. L., Valentine, F., Saag, M. S., Nelson, E. L., Sista, P. R., and Dusek, A. (2002) The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults, AIDS Res. Hum. Retroviruses 18, 685-693.
64. Wei, X., Decker, J. M., Liu, H., Zhang, Z., Arani, R. B., Kilby, J. M., Saag, M. S., Wu, X., Shaw, G. M., and Kappes, J. C. (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy, Antimicrob. Agents Chemother. 46, 1896-1905.
65. Baldwin, C. E., Sanders, R. W., Deng, Y., Jurriaans, S., Lange, J. M., Lu, M., and Berkhout, B. (2004) Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor, J. Virol. 78, 12428-12437.
66. Zwick, M. B., Jensen, R., Church, S., Wang, M., Stiegler, G., Kunert, R., Katinger, H., and Burton, D. R. (2005) Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1, J. Virol. 79, 1252-1261.
67. Burton, D. R., Desrosiers, R. C., Doms, R. W., Koff, W. C., Kwong, P. D., Moore, J. P., Nabel, G. J., Sodroski, J., Wilson, I. A., and Wyatt, R. T. (2004) HIV vaccine design and the neutralizing antibody problem, Nat. Immunol. 5, 233-236.
68. Kleid, D. G., Yansura, D., Small, B., Dowbenko, D., Moore, D. M., Grubman, M. J., McKercher, P. D., Morgan, D. O., Robertson, B. H., and Bachrach, H. L. (1981) Cloned viral protein vaccine for foot-and-mouth disease: responses in cattle and swine, Science 214, 1125-1129.